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Abstract
At the end of December 2019, in Wuhan, China, a rapidly spreading unknown 
virus was reported to have caused coronavirus disease of 2019 (COVID-19). 
Origin linked to Wuhan’s wholesale food market where live animals are sold. This 
disease is caused by SARS Coronavirus-2 (SARS-CoV-2), which is closely related 
to the Severe Acute Respiratory Coronavirus (SARS-CoV) and the Middle East 
Respiratory Syndrome Coronavirus (MERS-CoV). This virus shares a high sequence 
identity with bat-derived SARS-like Coronavirus, which indicating its zoonotic 
origin. The virus spread globally, provoking widespread attention and panic. This 
Coronavirus is highly pathogenic and causes mild to severe respiratory disorders. 
Later, it was declared a global pandemic by the World Health Organization (WHO) 
due to its highly infectious nature and worldwide mortality rate. This virus is a 
single-stranded, positive-sense RNA genome, and its genome length about 26 to 
32 kb that infects a broad range of vertebrates. The researchers worldwide focus on 
establishing treatment strategies on drug and vaccine development to prevent this 
COVID-19 pandemic. A drug repurposing approach has been used to identify a 
rapid treatment for the people affected by COVID-19, which could be cost-effective 
and bypass some Food and Drug Association (FDA) regulations to move quickly in 
phase-3 trials. However, there is no promising therapeutic option available yet. This 
book chapter addresses current information about the COVID-19 disease, including 
its origins, impacts, and the novel potential drug candidates that can help treat the 
COVID-19.
Keywords: COVID-19, Zoonotic virus, SARS-CoV-2, Epidemiology, Drug discovery, 
Therapeutics
1. Introduction
Nowadays, there is growing concern and perceived threat due to the outbreak 
of the novel coronavirus disease, COVID-19, as named by the World Health 
Organization (WHO), which poses a peril of pandemic to the global public health. 
The epicenter of the novel Coronavirus was located in Wuhan province of China, 
where the outbreak originated in December 2019 due to Severe Acute Respiratory 
Syndrome coronavirus 2 (SARS-CoV-2) [1]. This disease has spread to 220 coun-
tries, with over 158 million confirmed coronavirus cases of 3.3 million confirmed 
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deaths with 136 million recoveries worldwide as of May 10, 2021 [2]. Also, millions 
of people’s lives have been affected as mandatory isolations/quarantines instructed. 
The adverse effect of the COVID-19 outbreak could bring significant challenges to 
the health system globally and could have far-reaching consequences on the global 
economy if the virus’s spread is not effectively curtailed [3, 4].
Coronaviruses (CoVs) are encapsulated within a membrane envelope contain-
ing a single-stranded positive-sense RNA genome. Spikes of glycoprotein that give 
coronaviruses their crown-like appearance are studded with the viral membrane. 
Coronaviruses infect humans as well as animals such as bats that host the widest 
range of coronaviruses [5]. There are four types of alpha, beta, gamma, and delta-
designated coronaviruses. Extreme acute respiratory syndrome virus (SARS-CoV), 
Middle East respiratory syndrome (MERS-CoV), and SARS-CoV-2 are included in 
the beta coronavirus class [6, 7]. SARS-CoV-2 targets the lower respiratory system 
to induce viral pneumonia, similar to SARS-CoV and MERS-CoV, but may also 
affect the heart, kidney, liver, and central nervous system, resulting in multiple 
organ failure [8]. New evidence suggests that SARS-CoV-2 is more contagious/
transmissible than SARS-CoV and MERS-CoV [9]. Glycosylated spike (S) protein 
acts as a significant inducer of host immune responses, which mediates both SARS-
CoV and SARS-CoV-2 host cell invasion by binding with angiotensin-converting 
enzyme 2 (ACE2) located on the host cells of the surface membrane [1].
With the onset of the second wave of COVID-19 infection, developing countries 
like India seem to be reeling in the most catastrophic damages. Since late March of 
2021, the emergence of COVID-19 infected patience has skyrocketed to more than 22 
million people and have touched a record number of 4000 death per day in the first 
week of May 2021. The outbreak has left the country struggling hard to cope with the 
healthcare needs of patients. This silent killer disease creates havoc on earth, yet the 
upcoming course of this virus is unpredictable. Therefore, necessary measures are 
needed to control and eradicate this alarming problem to save the people’s precious 
life and the country’s economy [4, 10]. However, significant steps have been taken 
by the government of different countries. Many countries such as Italy, Germany, 
and India have “lockdown” the whole country to break the chain by quarantine and 
confinement of people to the homes. To date, there is no clinically approved antiviral 
drug or vaccine available to be used against COVID-19; therefore, it has posed a 
public health emergency and a global threat to the entire world. Repurposing exist-
ing medications is an affordable and effective therapeutic technique. The scientific 
community reacted quickly with a suggested list of current drugs with therapeutic 
potential for COVID-19, based on genomic sequence knowledge. This chapter 
examines the source of infection, the SARS-CoV-2 transmission pathway, and the 
medications currently being clinically tested for COVID-19 management to include 
references for follow-up research, prevention, and treatment that may help readers 
gain the latest understanding of this emerging infectious disease.
2. History
The first case of Coronavirus infection was detected in 1960. Twice in the past 
two decades, history has seen incidences where β-coronavirus has cross over from 
animal to humans in severe infectious diseases. Till 2003, coronavirus infection was 
considered to be a non-fatal disease. However, with many mortally affecting cases of 
severe acute respiratory syndrome cropping up in Hong Kong, the United States of 
America, Vietnam, Taiwan, and Thailand culminated in the deciphering of the deadly 
pathogenesis of this disease and led to the declaration of disease as a state emergency 
by World health organization (WHO) in 2004 [10–13]. In 2012, almost a decade later, 
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the Middle East respiratory syndrome coronavirus, also known as MERS-CoV, arose 
in Saudi Arabia, killing 858 and affecting 2494 people. This virus also originated from 
bats, and dromedary camels were possibly its intermediate host [14].
3. Origin and prevalence of COVID-19
It all started in the Hubei province’s capital city, Wuhan, in December 2019, 
when several adults with severe pneumonia were admitted to the nearby hospitals. 
The surveillance team was triggered and collected the samples of respiratory 
patients for the etiologic study. It was investigated that numerous patients had 
contact with the Huanan wholesale seafood, where dead and live animals were 
sold and traded. At the end of December 2019, China declared the outbreak of this 
disease to the WHO. This virus had more than 95% homology with bat coronavirus 
(SARS-like bat CoVs) and more than 70% resemblance with SARS-CoV, and hence 
the virus was recognized as Coronavirus on January 7, 2020. The environmental 
samples obtained from the Huanan seafood market were also tested positive, which 
indicated that the virus took origin from the Huanan seafood market [15]. Though 
the Coronavirus originated from bats, the existing possibility of an intermedi-
ary animal that gets transferred to humans may be snakes or pangolins. Xu. Et al. 
have isolated SARS-CoV-2 from pangolin and found pangolin to be the potential 
intermediate host of the SARS-CoV-2 as it shows high similarity (99%) between 
the coronaviruses affecting the humans [16]. However, these current results are not 
sufficient to prove the potential host and intermediate of COVID-19. Figure 1 shows 
a schematic view of crucial reservoirs and the mode of transmission of COVID-19.
According to Wu, JT, Leung et al. of York University, the estimated Basic 
Reproduction Number (R0), which means the average amount of second-
ary infection that patients may develop without intervention in a completely 
susceptible population, varies with several research groups [17]. Utilizing the 
Susceptible-Exposed-Infectious-Recovered (SEIR) model and Incidence Decay 
with Exponential Adjustment (IDEA) model, the estimated R0 value of novel 
COVID-19 was found to be 2.47–2.86 [18] and 2.0–3.3 [19] respectively, which is 
higher than other viruses of β–coronaviruses such as MERS-CoV (2.0–6.7) [20] 
and SARS-CoV (2.2–3.6) [21]. This elevated value of R0 points towards the fact that 
COVID-19 has a comparatively high transmission rate. It is also indicated from the 
overall case-fatality rate (CFR) that elderly male citizens are more prone to this 
Coronavirus, especially those with chronic health issues (heart disease, diabetes, 
hypertension) than other groups of the viruses. Thus, SARS-CoV-2 shows a high 
prevalence, and the population is easily susceptible to this virus. Among the RNA 
viruses, Coronavirus contains the most extensive genome sequence of about 26 to 
32 Kilobases with 14 Open Reading Frames (ORFs). These ORFs code for 27 struc-
tural and non-structural proteins of the virus [22, 23]. Spike protein, membrane 
protein, envelope, and nucleocapsid, along with eight accessory proteins, lie in the 
3′ end of the SARS-CoV-2 genome. A very high sequence resemblance is shared 
between structural proteins of SARS-CoV-2 and its predecessor human corona-
viruses (hCoVs) (82%) (except in the 8a, 8b, and 3b accessory protein); suggests 
common molecular pathophysiology and pathogenesis among COVID-19, SARS, 
and MERS [24]. Genomic analysis has surmised the relevance of the Sans N gene in 
coronaviruses. Positive selection, mutation, and adaptation affect the pathogenicity 
and stability of the virus and might play an essential role in widespread infection in 
a large population [25]. This also poses a threat to the generation of newer strains 
of the virus that may result from mutation and adaptation, making the threat of 
transmission even more potent [26].
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4. Drug repurposing
Drug repurposing is an old weapon in the arsenal for new drug development 
strategies. This approach identifies new therapeutic indications for available mar-
keted drugs making it time-efficient in a cost-effective manner [27, 28]. It has been 
assumed that about 75% of existing drugs could be repurposed for various diseases 
[29]. Global pandemic like novel coronavirus disease 2019 (COVID-19) has an 
urgent need to select appropriate therapeutic options with limited time to discover 
the new drug candidates [30]. It takes 10–15 years to develop a new drug, and the 
actual cost would be more than a billion dollars, with only 2.01% of its success rate 
Figure 1. 
Schematic view of the critical reservoirs and mode of transmission of coronaviruses.
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[31, 32]. Existing drug compounds, including Raltegravir, Paritaprevir, Bictegravir, 
and Dolutegravir, identify promising inhibitors against 3C-like protease 2′-O-ribose 
methyltransferase from COVID-19 is cost-effective and a drug repurposing 
approach [33, 34]. A recent in-silico study suggested that natural compounds like 
guggulsterone and drug rifampicin can be repurposed for COVID-19, insights from 
the molecular docking analysis [35, 36]. Thus, the concept of drug repurposing 
could be utilized as a novel drug discovery process to discover an effective thera-
peutic option against COVID-19. Recent examples of drug repurposing against 
COVID-19 are given in Table 1.
Based on previous experiences in the treatment of previous coronavirus diseases 
like SARS-CoV and MERS-CoV, drugs currently being implemented in the manage-
ment of this disease are entry or inhibitors of SARS-CoV-2, RNA mutagens that 
stop replication, host inflammatory response inhibitors, viral protease inhibitors, 
monoclonal antibodies (mAbs), and convalescent plasma-based immunogenicity, 
blockers of the release of mature virion and glucocorticoids based cell tissue and 
organ injury management apart from necessary ventilation for support [54]. It is an 
urgent need to perform more prospective, rigorous population studies and further 
preclinical and clinical trials to gain a perspective on the safety and therapeutic 
effect of new and potential therapeutic agents that may help contain the spread and 
enhance recovery from SARS-CoV-2 infection.
S.No. Drug name Primary use Description Ref.
1. Remdesivir Ebola Virus Disease Viral RNA polymerase inhibitor [37, 38]
2. Chloroquine & 
Hydroxychloroquine
Malaria Antimalarial; interferent with 
protein post-translational 
processes; Mitogen-activated 




3. Arbidol and Oseltamivir Treatment of 
influenza virus 
infections
Blocks virus entry into the cell [40, 
42–45]
4. Danoprevir Hepatitis C virus 
(HCV)
Nonstructural protein 3 (NSP3) 
inhibitor
[46]
5. Xiyanping Antibacterial and 
antiviral
Blocks virus entry into the cell [47]
6. Darunavir HIV protease 
inhibitor
Using among the COVID-19 
pneumonia patients
[48]
7. Thalidomide Anti-inflammatory 
action
Reduce tumor necrosis factor-α 
(TNFα), increase interleukins 
secretion, and activate natural 
killer cells
[49, 50]
8. Methylprednisolone Corticosteroid 
therapy
Prolongs the survival time 
among the severe stage COVID-
19 patients
[51, 52]
9. Lopinavir-Ritonavir HIV treatment Viral Protease inhibitors [40, 43]
10. Ribavirin Viral RNA synthesis 
inhibitor




Recent examples of drug repurposing against COVID-19.
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5. Drugs under clinical trials for COVID-19
As the epidemic spreads more and more, scientists worldwide are in a quest to 
explore drugs that may be potentially effective in combating COVID-19. During a 
pandemic that causes morbidity and mortality to grow exponentially, well-struc-
tured, randomized, controlled trials are necessary to evaluate new or repurposed 
drugs’ safety and efficacy to protect the community from ineffective, unnecessary, 
or unsafe drugs [55]. World Health Organization and partners have launched an 
international clinical trial – Solidarity trial, to assist in the accelerated search for 
a therapeutic regimen for COVID-19. Solidarity trail is one of the most extensive 
international randomized trials for COVID-19 to evaluate drugs on three essential 
outcomes that were needed for assisted ventilation, mortality, and duration of 
hospital stay. Solidarity Trial also aims to assess the chances of drugs improving sur-
vival or reducing the need for ventilation or hospital stay duration [56]. Currently, 
repurposed antiviral therapies are under significant scrutiny in clinical trials as 
disease-specific and designated antiviral therapy may have a maximum impact on 
disease progression and optimized treatment of COVID-19 [57].
5.1 RNA mutagens
RNA and DNA viruses encode RNA-dependent RNA polymerase (RdRp) core, 
which is requisite for RdRP catalytic function and viral replication. Hence, it is one 
of the prime targets for intervention infection. RdRp facilitates the elongation of the 
RNA strand and genome replication [7, 58]. RNA mutagens are nucleotide analogs 
that halt RNA elongation by RdRp by inserting themselves into the RNA chain. 
RdRp has no host cell homolog making this antiviral drug development superior as 
it reduces the risk of affecting human cells or protein. Thus, mutagenic nucleoside 
analog inhibitors like remdesivir, favipiravir, and ribavirin targeting RdRp are 
explored for their function to block viral RNA synthesis against human  
coronaviruses [7].
Remdesivir is a known antiviral against SARS-CoV and the MERS-CoV and 
has been a drug choice for SARS-CoV-2 due to its proven activity to inhibit SARS-
CoV-2 in vitro [59]. A randomized, placebo-controlled, double-blind trial of 
intravenous remdesivir in hospitalized adults suffering from lower respiratory 
tract infection due to COVID-19 shows an average recovery day of 14 days and 
clinical improvement at day 15, emphasizing that remdesivir abbreviate time to 
recovery among COVID-19 patients. The trial also suggested that a remdesivir 
treatment regimen may prevent disease progression to more severity and a lower 
incidence of respiratory support requirement [60]. Another randomized, open-
label trial among patients with severe COVID-19 who required oxygen support 
showed recovery among patients with both 5- and 10-day courses of remdesivir 
[61]. In another randomized phase 3 clinical trial, compared to standard of care 
treatment, the period of 5 days of remdesivir had significant improvement in 
patient’s clinical status [62]. Prompted by such conclusive evidence, the US Food 
and Drug Administration has granted remdesivir a status of Emergency Use 
Authorization for SARS-CoV-2 infected patients of about 12 years of age and with 
pneumonia [57].
Favipiravir is a broad-spectrum oral RNA-dependent RNA polymerase (RdRp) 
currently under study in numerous clinical and preclinical trials for its Role in 
inhibiting the viral replication phase of SARS-CoV-2. Glenmark Pharmaceuticals 
evaluates Favipiravir in Phase 3 clinical trial for COVID-19 among mild to moder-
ately infected patients of COVID-19 and has observed a marked 40% faster recov-
ery of patients by day 4 [63].
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In another prospective, randomized, controlled, open-label multicentered trial 
involving adult patients with COVID-19 in china, Favipiravir, compared to Arbidol, 
significantly improved the viral clearance, relief for pyrexia and cough with mild 
and manageable adverse effects [64]. Such promising results have cast the atten-
tion of healthcare providers to use RNA mutagens in treatments for SARS-CoV-2 
infection [65].
5.2 Protease inhibitors
Lopinavir/Ritonavir is a combination therapy used as a potent inhibitor of the 
human immunodeficiency virus protease. Lopinavir is a protease inhibitor that 
inhibits the protease enzyme necessary for the virus to catalyze the cleavage of 
polyprotein essential for completing the viral infectious cycle. In contrast, ritonavir 
is used in combination with Lopinavir to inhibit cytochrome P450 and increase its 
half-life for a longer duration of action [66]. Lopinavir/ritonavir was also employed 
in the treatment of MERS. In vitro experiments have shown lopinavir/ritonavir 
potential in limiting replication of Coronavirus. 400 mg Lopinavir with 50 mg 
Ritonavir (Kaletra) is an efficacious oral anti-HIV drug [67]. A study on  
SARS-CoV demonstrates the inhibitory activity of Lopinavir (4 μg/mL) in plaque  
reduction assay.
In contrast, combination therapy of Lopinavir (400 mg) and Ritonavir (100 mg) 
two times a day for 14 days in SARS-CoV infected patients exhibited lessening of 
viral load in patients [68]. Subsequently, a randomized control trial known as the 
MIRACLE trial (MERS-CoV Infection Treated With A Combination of Lopinavir/
Ritonavir and Interferon Beta-1b) was started to establish the therapeutic efficacy 
of combination therapy of interferon β-1b along with lopinavir/ritonavir among 
MERS-CoV infected patients [69]. Whereas in a retrospective case–control study, 
treatment by a combination of Lopinavir/Ritonavir (LPV/r) and Ribavirin yielded 
depreciated Acute Respiratory Distress Syndrome (ARDS) as well as mortality in 
SARS patients [70].
Darunavir (DRV), another protease inhibitor that shares a similar mechanism 
for inhibiting HIV replication, like Lopinavir, is in phase III studies. In combination 
with Cobicistat, Darunavir showed better efficacy and tolerability among Covid-19 
patients with less diarrhea and dyslipidemia and fewer adverse reaction compared 
with LPV/r [71].
5.3 Virus entry and fusion blockers
S proteins of Coronavirus interact with angiotensin-converting enzyme 2 
(ACE2) to initiate entry into the host cell, and hence ACE2 is a critical molecular 
target for drugs aiming to inhibit cellular access of SARS-CoV-2 [72]. Several drugs 
have been known to inhibit ACE2, and they are under significant scrutiny for clini-
cal studies.
Chloroquine and Hydroxychloroquine are the drugs from natural sources being 
employed as the first line of drugs, potential broad-spectrum antiviral drugs. 
Both are also being used to treat infection by SARS-CoV [73–75]. In Simian Vero 
cells, both chloroquine phosphate and Hydroxychloroquine have shown inhibition 
of replication of SARS-CoV-2, and in a physiologically-based pharmacokinetic 
model, 400 mg twice daily was established as the necessary dose [76, 77]. A pilot 
trial in about ten hospitals from Wuhan, Guangzhou, Jinzhou, Shanghai, Beijing, 
Chongqing, and Ningbo emphasizes Chloroquine phosphate’s superior ability to 
inhibit pneumonia, reduce viral load, and improving pulmonary findings, and 
reducing the duration of COVID-19 disease [77]. An open-label non-randomized 
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clinical trial demonstrated that in 57% of patients, COVID-19 patients who 
underwent treatment with a daily dose of 600 mg Hydroxychloroquine for six 
days showed virological clearance. In contrast, in another randomized clinical trial 
in Wuhan, sixty-two COVID-19 patients showed improvement in 5 days of treat-
ment by a daily dose of 400 mg hydroxychloroquine [39, 78]. This confirmation 
from the above smaller studies has propelled many prospective studies to investi-
gate Chloroquine and Hydroxychloroquine efficiency in patients of SARS-CoV-2 
infection [79, 80].
Umifenovir (Arbidol) is a drug that blocks virus entry inside the host cell by 
inhibiting endocytosis. It halts viral membrane from fusing into the host cell and 
subsequent viral entry and has been used in prophylaxis of influenza A and B 
viruses and inhibits numerous viruses, including Ebola virus, Hepatitis C virus, 
Lassa virus making it a critical antiviral [81–83]. Arbidol has been tested for its 
efficiency against COVID-19 conducted in Wuhan, China, where patients receiving 
400 mg Umifenovir showed reduced viral load and decreased mortality [84]. A 
retrospective cohort study among Umifenovir-treated patients showed malicious 
SARS−COV-2 detection by RT-PCR was, and 69% of patients had improved chest 
computed tomography scans [85]. These promising results have led to the clinical 
trial investigation of Umifenovir to be recently initiated [85–88].
Immunotherapy has proven to be effective against infectious diseases such as 
influenza, SARS, MERS, and Ebola, using monoclonal antibodies (mAbs) to miti-
gate contagious diseases [89]. Monoclonal antibodies bind to a specific target in the 
body, enabling it to mimic, block, or cause changes and provide a therapeutic effect 
for the particular diseases [90]. SARS-CoV-2 and SARS-CoV show many similarities 
among them, and this suggests the use of SARS antiviral monoclonal antibodies 
that can identify Receptor Binding Domain (RBD) in subunit S1 in SARS-CoV-2. 
mAbs can block RBD interaction and its ACE2 receptor, making it anti-spike pro-
tein therapy [91, 92]. A cocktail of monoclonal antibodies that can target S-proteins 
in SARS-CoV and detect different epitopes can potentially destroy viral cells. For 
example, a cocktail of monoclonal antibodies (MAB)- CR3022 show CR3022, 
and CR3014 showed neutralization in laboratory setup [92, 93]. Combination of 
Casirivimab and Imdevimab, popularly known as REGN-COV2 is a monoclonal 
antibody that can bind to SARS-CoV-2 spike protein and prevent it from entering 
healthy cells and is under scrutiny for the same. LY3819253- a mAb isolated from a 
recovered COVID-19 patient, is also under evaluation that has been sponsored by 
Eli Lilly and Company of Indianapolis, Indiana [94].
5.4 Virus-release blockers
Oseltamivir, branded as Tamiflu, is Food and Drug Admission (FDA) approved 
drug that acts as a neuraminidase inhibitor and has since been used popularly in 
treating influenza A and B [95]. Oseltamivir is being tried as a first-line antiviral 
drug in symptomatic patients with COVID-19 posts its successful use in SARS-CoV 
in 2003. A study by Zhang et al. brings light to the fact that that the active site of the 
Spike (S) 1 Protein of SARS shows a striking similarity to neuraminidase, making 
use of neuraminidase inhibitors useful to treat SARS-CoV [96]. Clinical trials are 
currently evaluating Oseltamivir in combination with favipiravir and Chloroquine 
in treating SARS-CoV-2 infection [97].
5.5 Non-virus-targeting treatments
Tocilizumab is a humanized mAb employed in Rheumatoid Arthritis treat-
ment, and numerous studies have included tocilizumab for consideration as 
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anti-SARS-CoV-2 therapy. A larger multicentred clinical trial of tocilizumab has 
been launched in China and had about 500 patients treated already enrolled [98, 99]. 
Anakinra is an FDA-approved modified human IL-1 receptor antagonist (IL-1RA) 
for RA treatment, which blocks innate immune response associated with cytokine 
storm resultant inflammation [100, 101].
Dexamethasone is a glucocorticoid that curbs lung injury resultant from inflam-
mation, respiratory failure, and death in ARDS by decreasing ventilator days 
and mortality. World Health Organization has put Dexamethasone on the list of 
essential medicines. National Institutes of Health has recommended glucocorticoids 
in patients hospitalized with Covid-19 in the United States [102]. Randomized 
Evaluation of COVID-19 Therapy (RECOVERY Trial) - a large human study was 
initiated in the United Kingdom by Oxford University in March 2020 to test the util-
ity of several previously known drugs against the COVID-19 trial. The initial report 
announced that Dexamethasone at a dose of 6 mg once daily for up to 10 days could 
bring down mortality significantly in critically ill COVID-19 patients validating 
the use of Dexamethasone for COVID-19 patients [103]. In another recent trial, 
dexamethasone therapy given to patients showed 15% lower mortality in ARDS 
patients [104].
CD24Fc, also known as Cluster of differentiation 24, is a recombinant fusion 
protein and a biological immunomodulator comprising the Fc region of human 
Immunoglobin G1 (IgG1) attached to the nonpolymorphic areas of CD24, making 
it an innate checkpoint against the inflammatory responses against tissue injuries 
associated with cytokine storm. The protection and biological activity of CD24Fc in 
suppressing the expression of multiple inflammatory cytokines have been dem-
onstrated in preclinical and clinical studies carried out. A Phase II clinical trial in 
patients with leukemia indicates that three doses of CD24Fc effectively eliminated 
the appearance of extreme acute Graft vs. Host Diseases (GVHD) due to overreact-
ing immune system and recipient target attacking transplanted T cells. CD24Fc may 
therefore be investigated as a prime candidate for non-antiviral COVID-19 therapy 
intervention for the control of cytokine storms in affected cells [105].
Dapagliflozin (Farxiga), a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, 
has currently been assessed under “Dapagliflozin in Respiratory Failure in Patients 
with COVID-19” or DARE-19 in a phase-3 randomized trial designed to evaluate 
its efficacy as a treatment option for COVID-19 at risk of developing comorbidity 
such as organ failure [106]. SGLT-2 inhibitors play a role in instigating the renin-
angiotensin-aldosterone pathway through the expression of angiotensin-converting 
enzyme type-2 (ACE2). Renin-angiotensin-aldosterone system (RAAS) pathway 
is essential in the pathophysiology of SARS-CoV-2. Organ-protective effects are 
provided by SGLT-2 inhibitors complementary to its glycaemic benefits and hence 
may afford additional vital organ protection to the patients [107, 108]. Patients in 
DARE-19 are to be treated with a daily dose of 10 mg Dapagliflozin once a day.
6. Future prospective
The evolution of Zoonotic Chinese Coronavirus SARS-CoV-2 needs to be 
better monitored through implementing better surveillance and precautionary 
steps. Due to this COVID-19 pandemic, scientists worldwide were encouraged to 
search for novel therapeutic options, including vaccines, drugs, and diagnostics. 
However, until now, there is no effective treatment approved and recommended 
for COVID-19 globally. Utilization of such computer-aided-drug design (CADD) 
and bioinformatics tools such as Immune Epitope Database (IEDB) software to 
predict a computational vaccine and target drug compounds for COVID-19 is 
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also encouraging [109]. In this way, drug repurposing emerged as a promising 
therapeutic approach in a time-saving and cost-effective manner. There are many 
drugs repurposed in the case of COVID-19 treatment. Drugs like Remdesivir, 
Dexamethasone, and a combination of Lopinavir-Ritonavir, reported positive 
outcomes to treat COVID-19.
Similarly, there are currently more than 100 vaccine candidates under develop-
ment for the COVID-19, and it will likely be ready by early/late 2021. 38 Vaccines 
are in the first stage for the testing safety and dosage, 17 Vaccines are in their 
second phase and expanded safety trials, 12 Vaccines are in the third phase comes in 
large-scale efficacy tests, and 6 Vaccines approved for first or limited use. None of 
the vaccines are approved for full use. The safety issue is concerning and the most 
significant challenge when tested in diverse populations, especially in countries like 
India and China. Large-scale production, storage, and distribution of vaccines are 
also another challenge. However, further investigations and experiments are needed 
to discover an effective treatment option.
7. Conclusion
The Zoonotic Chinese Coronavirus SARS-CoV-2 outbreak likely started in 
the seafood market in Wuhan, China, where live animals are sold. The spread of 
this disease has been declared a global pandemic by WHO as it rapidly expanded 
worldwide and still infecting people exponentially. However, it is suggested that 
bats are the natural hosts for SARS-CoV-2. Bat-derived coronavirus identified from 
a sequence analysis shares 93.3% nucleotide identity with SARS-CoV-2 complete 
virus genome and 97.2% identity in the 1ab gene. However, the origins of the virus 
remain unclear. There is no effective therapeutic option available against human 
coronaviruses. This pandemic may get worsened soon if no effective therapeutics or 
vaccine is developed to combat COVID-19.
Nevertheless, researchers and scientists are searching for the vaccines or/
and drugs used against this deadly virus. Different broad-spectrum medications, 
including repurposed antiviral drugs, either alone or in combinations, are evalu-
ated for their efficacy to treat COVID-19 patients. Few drugs give positive results to 
block the COVID-19 infection, including Remdesivir, Oseltamivir, Lopinavir, and 
Ritonavir. A predictive analysis says that more such viral pandemic could emerge 
shortly and cause deadly outbreaks. Therefore, to prevent the emergence of a new 
viral pandemic, strategies should be developed to minimize its consequences.
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